Overview

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

Phase:

PHASE2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide